Browsing Tag
UroGen Pharma
3 posts
A $50m quarter changes the stakes for UroGen as UGN-103 reaches FDA
UroGen files UGN-103 with the FDA as ZUSDURI sales surge 73%, potentially extending its fast-growing bladder cancer franchise into 2044.
Can reimbursement unlock the next wave of office-based cancer care? What ZUSDURI and CMS J-codes reveal about oncology’s outpatient shift
Can J-codes like ZUSDURI’s drive the next wave of office-based cancer care? Find out why 2026 could be a turning point in outpatient oncology.
Will UroGen Pharma’s reimbursement tailwind in 2026 turn ZUSDURI into a category-defining cancer therapy?
UroGen Pharma sets $1B peak sales goal for ZUSDURI as permanent J-code from 2026 is expected to drive widespread adoption in outpatient urology settings.